Africa’s Biopharma
Future, Driven
by Innovation

Africa’s Biopharma Future,
Driven by Innovation

Africa imports over 70% of its biopharmaceuticals. We are changing this by innovating and manufacturing locally, at affordable costs and in line with global GMP standards.

OUR MISSION

To build Africa’s GMP-grade biomanufacturing capacity and deliver safe, affordable, high-quality vaccines and advanced therapies.

OUR VISION

To advance Africa’s health sovereignty through world-class quality, bold innovation and sustainable self-reliance in biopharmaceutical manufacturing.

OUR VALUES

Quality & Compliance: Uncompromising GMP standards and regulatory excellence in every batch
Integrity & Ethics: Transparent, accountable leadership & responsible conduct across all partnerships.
Innovation & Improvement: Science-led progress powered by learning, data & continuous refinement.
Collaboration & Impact: Strong partnerships & teamwork that deliver measurable health outcomes.

A historic milestone

Uganda & Türkiye Sign Landmark Health Partnership at Hacettepe University

WE ARE DEVELOPING A PIPELINE OF FIRSTS

To become Africa’s leading Center of Excellence in Biomanufacturing, driving health sovereignty, innovation, self-reliance and sustainable development for future generations.

Dive In

The Backstory

The Vaccine Access Initiative (VAi), a subsidiary of Microhaem Scientifics (MHS), is driving Africa’s transformation from health dependency to self-reliance. Founded to localize vaccine and stem cell manufacturing, VAI strengthens the continent’s capacity to deliver timely, affordable, and high-quality healthcare—empowering Africa to innovate for itself.